Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Publication of GT199800049ApublicationCriticalpatent/GT199800049A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
LOS INHIBIDORES DE LA PROTEASA DEL VIH, OBTENIBLES POR SINTESIS QUIMICA, INHIBEN O BLOQUEAN LA ACTIVIDAD BIOLOGICA DE LA ENZIMA DE LA PROTEASA DEL VIH, HACIENDO QUE TERMINE LA REPLICACION DEL VIRUS DEL VIH. ESTOS COMPUESTOS, ASI COMO LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ESTOS COMPUESTOS Y OPCIONALMENTE OTROS AGENTES ANTIVIRICOS COMO INGREDIENTES ACTIVOS, SON APTOS PARA TRATAR A PACIENTES O HUESPEDES INFECTADOS CON EL VIRUS DEL VIH, QUE SE CONOCE COMO CAUSA DEL SIDA. ESTOS COMPUESTOS TIENEN LA ESTRUCTURA QUIMICA QUE SE PRESENTA A CONTINUACION, EN LA R Y R1, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE.INHIBITORS OF HIV PROTEASE, OBTAINABLE BY CHEMICAL SYNTHESIS, INHIBIT OR BLOCK THE BIOLOGICAL ACTIVITY OF THE HIV PROTEASE ENZYME, CAUSING THE REPLICATION OF HIV VIRUSES TO END. THESE COMPOUNDS, AS WELL AS THE PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND OPTIONALLY OTHER ANTIVIRIC AGENTS AS ACTIVE INGREDIENTS, ARE SUITABLE FOR TREATING PATIENTS OR GUESTS INFECTED WITH HIV VIRUSES, WHICH ARE KNOWN AS AIDS CAUSES. THESE COMPOUNDS HAVE THE CHEMICAL STRUCTURE BELOW, IN THE R AND R1, THEY ARE FUNCTIONAL GROUPS DESCRIBED IN THE FILE.
GT199800049A1997-03-131998-03-12
METHOD FOR OBTAINING VHI PROTEASE INHIBITORS.
GT199800049A
(en)
USE OF A D1 / D5 ANTAGONIST FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT OBSESSIVE COMPULSIVE DISORDERS, SOMATOFORM DISORDERS, DISTOCIATIVE DISORDERS, EAT DISORDERS, PULSE CONTROL AND AUTISM DISORDERS